Aurinia Pharmaceuticals Inc (AUPH)

[zzaatt]

You also have to consider that with more blacks and Hispanics the placebo CR will also go down

Good point.


In addition I think one needs a bit of interpretation of CoolG's statement:

in P3 you have 55% of the sites in US (Black, White, Hispanic), South America (Hispanic), Spain (Hispanic), South Africa (Black); this is a clear indication that the Black and Hispanic races will form a major part of the P3 trial;

Let's not confuse social and cultural distinctions and race specific (DNA based) differences.

"Hispanics" of Spain are different racially compared to S.American "hispanics". Cultural norms and standards of care are also very different, and are a confounding factor that is difficult to fully factor into the calculations.

I'm betting that social conditions and access to medical care will be more important. So, the selection of "higher" quality trial sites should be more significant.